Translational Development Acquisition Corp. and battery maker ProLogium have amended their planned business combination, setting a $3.9 billion equity value for ProLogium and revising how its shares will be reorganized before the deal closes. The changes also clarify how certain founder warrants will convert and set out the planned composition of the combined company’s board.
The amendment changes the transaction’s share-recapitalization process and establishes a new three-class share structure for ProLogium. It does not, by itself, complete the business combination.
Key details
-
ProLogium’s agreed equity value is $3.9 billion. That consists of a $3.8 billion enterprise value plus $100 million of agreed net cash.
-
The share calculation uses 93.7 million ProLogium shares. The total includes 89.4 million issued common and preferred shares, 2.6 million shares underlying specified warrants, and 1.7 million shares reserved for the company’s equity incentive plan. Warrant and plan shares are counted even if the warrants have not been exercised or options have not been granted.
-
The consolidation factor is 4.16. Before the first merger takes effect, each existing ProLogium share will be cancelled in exchange for 4.16 new ordinary shares, with fractional entitlements aggregated and rounded. The factor may be adjusted for specified changes to ProLogium’s share capital before closing. Exercises or issuances already represented in the agreed share count will not, on their own, trigger an adjustment.
-
Shareholders will receive different classes of ProLogium shares based on their ownership group. Founder-held shares will be exchanged for Class B shares. Shares held by SBCVC Fund IV, New Epoch Capital and the two New Horizon holding companies will become Class C shares. Other shareholders will receive Class A shares.
-
ProLogium plans to adopt a new share structure at closing. Its authorized capital will be 2.5 billion shares: 1.2 billion Class A, 500 million Class B, 700 million Class C and 100 million shares in classes its board may determine under the new articles. The amendment does not describe the different voting or economic rights of these classes in the text provided.
-
The amendment defines the cash available at closing. It will include funds released from TDAC’s trust after shareholder redemptions, plus net proceeds from the planned private investment that TDAC has actually received and can use immediately before closing. The amendment does not state the amount of cash that will ultimately be available.
-
Certain ProLogium founder warrants will be adjusted for the recapitalization. Their underlying share count will increase by the 4.16 factor and their per-share exercise price will be divided by that factor. If held by a founder immediately before the recapitalization, the warrants will be exercisable for Class B shares; if held by someone else, they will be exercisable for Class A shares. A warrant transferred to a non-founder on or after the recapitalization will thereafter be exercisable only for Class A shares.
-
The post-closing board is planned to have nine directors, divided as evenly as possible into three classes. TDAC and its sponsor will designate one director, expected to be Michael B. Hoffman. ProLogium founder Yang Szu-Nan will designate three directors, including himself. SBCVC and New Epoch will each have the right to appoint one director. New Horizon I will be able to recommend one independent director to serve at closing. At least three board members must qualify as independent under applicable U.S. listing rules.
Plain-English implications
The amendment fixes a valuation and share-conversion framework for ProLogium ahead of closing, while separating ownership into three share classes tied to different shareholder groups. It also makes closing cash dependent on both TDAC shareholder redemptions and the private investment proceeds actually received. The terms described set out several board appointment rights, but do not specify the appointments for all nine seats.
